Trial Profile
A prospective, multicenter registry of high-risk patients treated with Umirolimus stent [Nobori]
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Sep 2017
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms INSPIRE-1
- 30 Aug 2017 Results comparing 1 year stent-related clinical outcomes of coronary Amphilimus-eluting stent versus biodegradable-polymer Biolimus-eluting stent from this and ASTUTE registry, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
- 15 Sep 2015 New trial record